Bufexamac

• Description :

  Bufexamac is a selective IIb HDAC (HDAC6, HDAC10) and LTA4H dual inhibitor, with Kds of 0.53 µM and 0.22 µM for HDAC6 and HDAC10. Bufexamac is a nonsteroida anti-inflammatory drug[1][2][3].

• CAS Number :

  [2438-72-4]

• Product Name Alternative :

  Bufexamic acid

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H312, H332

• Target :

  Aminopeptidase; HDAC

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage; Epigenetics; Metabolic Enzyme/Protease

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Cancer; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/bufexamac.html

• Purity :

  98.0

• Solubility :

  DMSO : ≥ 100 mg/mL|H2O : < 0.1 mg/mL

• Smiles :

  O=C(NO)CC1=CC=C(OCCCC)C=C1

• Molecular Formula :

  C12H17NO3

• Molecular Weight :

  223.27

• Precautions :

  H302, H312, H332

• References & Citations :

  [1]Bantscheff M, et al. Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotechnol. 2011 Mar;29 (3) :255-65.|[2]Oehme I, et al. Histone deacetylase 10 promotes autophagy-mediated cell survival. Proc Natl Acad Sci U S A. 2013 Jul 9;110 (28) :E2592-601.|[3]Xiao Q, et al. Bufexamac ameliorates LPS-induced acute lung injury in mice by targeting LTA4H. Sci Rep. 2016 Apr 29;6:25298. |[4]Schölz C, et al. Acetylation site specificities of lysine deacetylase inhibitors in human cells. Nat Biotechnol. 2015 Apr;33 (4) :415-23.|[5]Suominen MM, et al. Effects of intra-articular injections of bufexamac suspension in healthy horses. Am J Vet Res. 2001 Oct;62 (10) :1629-35.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• Isoform :

  HDAC10; HDAC3; HDAC6; HDAC8